Respiratory
Latest news
198 articles · 20 / page
SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurr
PLCOm2012 Risk-Based Selection Outperforms NELSON Criteria for Lung Cancer Detection in Germany: Findings from the HANSE Cohort
In HANSE, PLCOm2012 (6‑year risk ≥1.58%) selected more lung cancers and yielded a lower number needed to screen than NELSON criteria, supporting risk-model selection for CT screening programs, with caveats on generalisability and mortality
Rising Inhaler Emissions in the US: 1.6 Billion Devices, 25 Million Tons CO2e, and $5.7B in Social Costs
A JAMA serial cross‑sectional analysis finds US outpatient inhaler dispensing (2014–2024) produced ~24.9 million metric tons CO2e, mostly from metered‑dose inhalers; policy and clinical shifts to dry‑powder/soft‑mist devices and low‑GWP pro
Morphine Does Not Relieve Chronic Breathlessness: The MABEL Trial Finds No Benefit and Signals More Harms
A UK multicentre randomized placebo‑controlled trial (MABEL) showed no improvement in worst breathlessness with low‑dose oral morphine versus placebo at 28 days, with more adverse events and withdrawals in the morphine arm.
Bivalent RSV pre‑F Vaccine Dramatically Reduces RSV‑Associated Hospitalisations and Chronic‑Disease Exacerbations in Adults Aged 75–79 Years
In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung d
Voriconazole Not Superior to Itraconazole for Chronic Pulmonary Aspergillosis: VICTOR-CPA Trial Reaffirms Itraconazole as First-Line in India
A randomized trial in India found no superiority of oral voriconazole over itraconazole for chronic pulmonary aspergillosis at 6 months; efficacy was similar, but voriconazole caused more adverse events.
Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)
The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even
What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials
A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.
Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c
Boosting Sleep Apnea Diagnosis After Stroke: A Quality Improvement Breakthrough
A quality improvement program significantly increased obstructive sleep apnea testing in stroke and TIA patients, advancing guideline-based care in cerebrovascular health.
Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial
A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.
Persistent Inspiratory Muscle Weakness After Prolonged Intubation: MIP at Day 12 Predicts Failure to Recover in the Acute-Care Stay
In patients extubated after ≥7 days of mechanical ventilation, 43% had persistent inspiratory muscle weakness at hospital discharge. Maximal inspiratory pressure (MIP) measured 12 days after diagnosis strongly predicted persistent weakness
Prolonged Prone Positioning in ARDS: Current Evidence Is Inconclusive — No Clear Mortality or Safety Benefit
A systematic review and meta-analysis found no clear mortality, oxygenation, or safety benefit for prolonged prone positioning (≥24 h) in ARDS; evidence is low to very low certainty and does not support routine use outside clinical trials.
RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease
In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing at
Nirsevimab Halves RSV Bronchiolitis Risk in Infants — High Effectiveness Sustained Despite Emergent RSV‑B Mutations
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
Nirsevimab Cuts RSV Lower Respiratory Infections in Infants Without Replacing Other Viruses: Post‑hoc Analysis of the Phase 3 MELODY Trial
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants
A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to preven
Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Circulating Endothelial Transcriptomic Signatures Predict Worse Outcomes in COVID-19, Respiratory Failure and ARDS
Transcriptomic deconvolution of blood identifies elevated circulating endothelial signatures (ECS%) that associate with higher 28‑day mortality and worse respiratory trajectories in pediatric respiratory failure and adults hospitalized with
Browse by specialty
Open language-specific specialty feeds and department pages.